Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer

Miho Takao, Aikou Okamoto, Takashi Nikaido, Mitsuyoshi Urashima, Satoshi Takakura, Misato Saito, Motoaki Saito, Sanshiro Okamoto, Osamu Takikawa, Hiroshi Sasaki, Makoto Yasuda, Kazunori Ochiai, Tadao Tanaka
Oncology reports · 2007 · vol. 17(6) , pp. 1333–9 · doi:10.3892/or.17.6.1333 · PMID:17487387 · W2059987574
article OA: bronze CC0
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Increased indoleamine-2,3-dioxygenase protein synthesis was positively associated with impaired survival in serous ovarian cancers, but not in clear cell or endometrioid types.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 · read from full text ⓘ

This study investigated whether indoleamine-2,3-dioxygenase (IDO) protein expression relates to survival across different histological types of ovarian cancer by analyzing immunohistochemical IDO staining in 122 tumors (40 serous adenocarcinomas [SA], 67 clear cell adenocarcinomas [CCA], and 15 endometrioid adenocarcinomas [EA]), with some cases accompanied by endometriosis and/or lymph node metastasis. IDO staining was positive in 57.5% of SA, 49.2% of CCA, and 73.3% of EA, and for advanced-stage SA treated with optimal surgery plus paclitaxel-carboplatin, higher IDO staining score correlated with worse overall survival; however, no such association was observed for CCA. IDO staining patterns also matched between CCA and coexisting endometriosis in most CCA-with-endometriosis cases, and the primary-to-metastatic correspondence was common in lymph node metastatic cases. The paper is limited to associations derived from immunohistochemistry and Kaplan–Meier analysis rather than mechanistic testing. Relevance to endometriosis: the authors report that in CCA cases accompanied by endometriosis, IDO staining patterns in CCA were identical to those in the endometriosis lesions, though the paper’s main focus is prognosis and histologic-type–specific associations of IDO in ovarian cancer rather than endometriosis itself.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

We previously reported that indoleamine-2,3-dioxygenase (IDO) is associated with paclitaxel resistance and that IDO serves as a marker of poor prognosis in ovarian serous adenocarcinomas (SA). In this study, to explore the role of IDO in the development of various histological types of ovarian cancer, we further examined IDO expression not only in SA but also in other types of ovarian cancers. Expression of IDO protein was analyzed by immunohistochemistry for a total of 122 ovarian cancers including 40 SA, 67 clear cell adenocarcinomas (CCA), and 15 endometrioid adenocarcinomas (EA) with informed consent. Among these cases, there were 11 CCA accompanied with endometriosis and 60 cases with lymph node metastasis. We classified the samples into four categories by IDO staining pattern. IDO staining was positive in 57.5% of SA, 49.2% of CCA, and 73.3% of EA, respectively. The Kaplan-Meier survival curve showed a clear relationship between staining score and overall survival for patients with advanced (stages III and IV) SA (n=33) who underwent optimal surgery and paclitaxel-carboplatin (TC) chemotherapy as a first-line regimen. There was no association between IDO staining score and overall survival in the CCA cases. Eight of 11 cases (72.7%) of CCA accompanied by endometriosis presented identical staining patterns of IDO between CCA and endometriosis. In 43 of 60 cases (71.6%) with lymph node metastasis, the staining patterns of IDO showed a correspondence between the primary lesion and metastatic site. These results suggested that the increased synthesis of IDO protein was positively associated with impaired survival only in the serous type of ovarian cancer.
Full text 4,844 characters · extracted from oa-doi-fallback · click to expand
Print ISSN: 1021-335X Online ISSN: 1791-2431 International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease. International Journal of Oncology is an international journal devoted to oncology research and cancer treatment. Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery. Oncology Reports is an international journal devoted to fundamental and applied research in Oncology. Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine. Oncology Letters is an international journal devoted to Experimental and Clinical Oncology. Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology. International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis. Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology. Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition. Publishes open-access research on using epigenetics to advance understanding and treatment of human disease. An International Open Access Journal Devoted to General Medicine. Article - Authors: - Pages: 1333-1339|Published online on: June 1, 2007https://doi.org/10.3892/or.17.6.1333 - Expand metrics + We previously reported that indoleamine-2,3-dioxygenase (IDO) is associated with paclitaxel resistance and that IDO serves as a marker of poor prognosis in ovarian serous adenocarcinomas (SA). In this study, to explore the role of IDO in the development of various histological types of ovarian cancer, we further examined IDO expression not only in SA but also in other types of ovarian cancers. Expression of IDO protein was analyzed by immunohistochemistry for a total of 122 ovarian cancers including 40 SA, 67 clear cell adenocarcinomas (CCA), and 15 endometrioid adenocarcinomas (EA) with informed consent. Among these cases, there were 11 CCA accompanied with endometriosis and 60 cases with lymph node metastasis. We classified the samples into four categories by IDO staining pattern. IDO staining was positive in 57.5% of SA, 49.2% of CCA, and 73.3% of EA, respectively. The Kaplan-Meier survival curve showed a clear relationship between staining score and overall survival for patients with advanced (stages III and IV) SA (n=33) who underwent optimal surgery and paclitaxel-carboplatin (TC) chemotherapy as a first-line regimen. There was no association between IDO staining score and overall survival in the CCA cases. Eight of 11 cases (72.7%) of CCA accompanied by endometriosis presented identical staining patterns of IDO between CCA and endometriosis. In 43 of 60 cases (71.6%) with lymph node metastasis, the staining patterns of IDO showed a correspondence between the primary lesion and metastatic site. These results suggested that the increased synthesis of IDO protein was positively associated with impaired survival only in the serous type of ovarian cancer. Copy and paste a formatted citation Spandidos Publications style Takao M, Okamoto A, Nikaido T, Urashima M, Takakura S, Saito M, Saito M, Okamoto S, Takikawa O, Sasaki H, Sasaki H, et al: Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep 17: 1333-1339, 2007. APA Takao, M., Okamoto, A., Nikaido, T., Urashima, M., Takakura, S., Saito, M. ... Tanaka, T. (2007). Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncology Reports, 17, 1333-1339. https://doi.org/10.3892/or.17.6.1333 MLA Takao, M., Okamoto, A., Nikaido, T., Urashima, M., Takakura, S., Saito, M., Saito, M., Okamoto, S., Takikawa, O., Sasaki, H., Yasuda, M., Ochiai, K., Tanaka, T."Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer". Oncology Reports 17.6 (2007): 1333-1339. Chicago Takao, M., Okamoto, A., Nikaido, T., Urashima, M., Takakura, S., Saito, M., Saito, M., Okamoto, S., Takikawa, O., Sasaki, H., Yasuda, M., Ochiai, K., Tanaka, T."Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer". Oncology Reports 17, no. 6 (2007): 1333-1339. https://doi.org/10.3892/or.17.6.1333

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Biomarkers, Tumor Cystadenocarcinoma, Serous Indoleamine-Pyrrole 2,3,-Dioxygenase Ovarian Neoplasms Biomarkers, Tumor Biomarkers, Tumor Cystadenocarcinoma, Serous Cystadenocarcinoma, Serous Cystadenocarcinoma, Serous Female Humans Immunohistochemistry Indoleamine-Pyrrole 2,3,-Dioxygenase Indoleamine-Pyrrole 2,3,-Dioxygenase Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Prognosis Survival Rate Up-Regulation

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (25)

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:15:00.519696+00:00
License: CC0 · commercial use OK